Since NKG2D expression and NK cell function are known to be modulated by the presence of NKG2D ligands released from cells (53–55) as well as cytokines such as TGFβ (56–58), we tested whether the levels of these molecules were augmented in plasma from COVID-19 patients with life-threatening disease. The gene discussed is KLRK1; the disease is COVID-19.